In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Roger Lias, Chief Executive Officer at Stelis Biopharma. A fellow-Brit, Roger is a graduate of the University of Southampton. He also holds a PhD in Biotechnology from the University of Cambridge. His experience of the biopharma CDMO space in particular spans over 30 years including roles with the likes of Lonza, Diosynth, KBI Biopharma, Cytovance Biologics, Eden Biodesign, Allergen and Avid Bioservices and of course, Stelis. During the early part of his career, he moved to North America and now lives in California. 
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain (and a whole load more) with Roger, covering an incredible 30 year journey at the heart of the biologic drug development explosion, including roles with the 'who’s who' of large molecule CDMOs. Roger speaks about what it was like creating a biologics CMO from the ground-up in the 90s with no obvious market. Raman and Roger discuss the value of being curious, energetic, open-minded and simply building relationships as the pillars to a long, successful career in the outsourcing space. Lastly, Roger speaks on the trend towards a closer collaboration between CDMO competitors, after all, nobody can do everything.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.